Is compass pathways a buy
WebApr 9, 2024 · COMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to analysts' consensus price target of … According to the issued ratings of 5 analysts in the last year, the consensus ratin…
Is compass pathways a buy
Did you know?
Web15 hours ago · Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology … WebApr 11, 2024 · finance.yahoo.com - November 2 at 5:54 PM. COMPASS Pathways plc's (NASDAQ:CMPS) market cap increased by US$60m, insiders receive a 33% cut. finance.yahoo.com - October 29 at 1:03 PM. COMPASS Pathways plc to announce third quarter 2024 financial results on 3 November 2024. finance.yahoo.com - October 26 at …
WebMar 27, 2024 · Compass Pathways PLC CMPS: Mental health company Compass Pathways moves up seven positions to rank fourth for the week. Data shows 33.8% of the float short and a cost to borrow of 20.7%. Web2 days ago · COMPASS Pathways (CMPS) In a report released today, Elemer Piros from EF Hutton reiterated a Buy rating on COMPASS Pathways, with a price target of $38.00. The …
WebJan 10, 2024 · COMPASS Pathways' cash burn of US$62m is about 7.9% of its US$787m market capitalisation. ... It does not constitute a recommendation to buy or sell any stock, and does not take account of your ... WebApr 7, 2024 · As of April 06, 2024, COMPASS Pathways PLC had a $428.9 million market capitalization, putting it in the 54th percentile of companies in the Biotechnology & …
WebBuy Compass Pathways Plc Stocks Fact checked Compass Pathways Plc is a medical care facilities business based in the US. Compass Pathways Plc stocks (CMPS.US) are listed …
WebCompass Pathways is a mental-health-focused pharmaceutical company that is developing psilocybin-based treatments for patients suffering from depression. Founded in 2016, the company has developed a proprietary form of psilocybin called COMP360 for cases of major depressive disorder that resist more traditional treatment options. coconut bike cup holderWebApr 14, 2024 · Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways has a consensus rating of “Buy” and an average price target of $47.00. coconut biscuits history facts point 15WebApr 2, 2024 · I reaffirmed a “buy” rating and issued a $38.00 price target on shares of COMPASS Pathways in a report on Tuesday, February 28th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $47.00. COMPASS Pathways Price … coconut beach thailandWebDec 26, 2024 · Despite having an IPO just three months ago, Compass Pathways ( CMPS 5.84%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 … coconut benefits during pregnancyWeb1 day ago · That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. ... COMPASS Pathways to participate in ... coconut biscuits history facts point 16WebApr 12, 2024 · EF Hutton analyst Elemer Piros reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $38 price target. coconut beach volleyball complexWebSee the Price Targets and Ratings of: All Analysts Top Analysts Premium CMPS Analyst Ratings Strong Buy 7 Ratings 7 Buy 0 Hold 0 Sell Based on 7 analysts giving stock ratings to COMPASS Pathways in the past 3 months CMPS Stock 12 Months Forecast $44.14 (337.90% Upside) cal lutheran admitted students